FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to process of crystallisation, obtaining and isolation of novel crystalline form of fusidic acid, to application of said processes in production of pharmaceutical composition or medication, and to application of said form of crystalline fusidic acid in treatment of bacterial infections.
EFFECT: obtaining pharmaceutical composition for treatment of bacterial infections.
11 cl, 10 ex, 1 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FORM OF SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENESULFONAMIDE | 2012 |
|
RU2607515C2 |
| MULTICOMPONENT CRYSTALS COMPRISING DASATINIB AND SELECTED COCRYSTAL FORMERS | 2013 |
|
RU2650524C2 |
| POLYMORPHIC FORMS OF SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENESULPHONAMIDE | 2012 |
|
RU2607191C2 |
| POLYMORPHIC FORMS OF SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENESULPHONAMIDE | 2012 |
|
RU2607514C2 |
| SOLID FORMS OF TRANSTHYRETIN DISSOCIATION INHIBITOR | 2012 |
|
RU2586330C2 |
| CRYSTALLINE FORM OF 13-[(N-TERT-BUTOXYCARBONYL)-2'-O-HEXANOYL-3-PHENYLISOSERINYL]-10-DIACETYLBACCATIN III | 2011 |
|
RU2546661C2 |
| DASATINIB SALTS IN CRYSTALLINE FORM | 2014 |
|
RU2662805C2 |
| SOLID FORMS OF MACROLIDES | 2008 |
|
RU2476438C2 |
| NEW POLYMORPHIC FORM OF A CALCIEMETRIC COMPOUND | 2011 |
|
RU2599788C2 |
| 2-[4-(METHYLAMINOMETHYL)PHENYL]-5-FLUORO-BENZOFURAN-7-CARBOXAMIDE HYDROCHLORIDE POLYMORPHOUS, METHOD FOR ITS PRODUCTION AND APPLICATION | 2018 |
|
RU2783418C1 |
